CytomX Q2 2022 revenue $18M; cash $228M; restructuring extends runway to 2025

CytomX Therapeutics, Inc.

Cash and investments $228M at June 30, 2022, down from $305M at Dec 31, 2021.
Total revenue $18M for Q2 2022, up from $16M in Q2 2021; R&D expense $31M (+$5M YoY).
Company restructuring announced July 2022 aims to extend cash runway into 2025.
IND filings planned for CX-801 (IFN alpha-2b) and CX-2051 (EpCAM ADC) in H2 2023.
CX-2029 data update for squamous NSCLC expected Q4 2022; praluzatamab ravtansine also updating Q4 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.